Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024

MAIC between ALPINE & ASCEND: A matching-adjusted indirect comparison (MAIC) was conducted using individual patient data from the ALPINE trial and aggregate data from the ASCEND trial to compare the efficacy of zanubrutinib and acalabrutinib in patients with relapsed/refractory CLL.